Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach

References

• Aebi, H., 1984. Catalase in, vitro. Methods in Enzymology, 105, 121–126.
   PubMed Web of Science ®Google Scholar
• Agrawal, U., Raju, R., and Udwadia, Z.F., 2020. Favipiravir: a new and emerging antiviral option in COVID-19. Medical Journal, Armed Forces India, 76 (4), 370–376.
   PubMedGoogle Scholar
• Algül, Ö., Dar, B.P.W., and Öksüz, Z., 2019. Antiviral ilaçlardaki gelişmeler ve değerlendirilmesi. Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi, 9 (2), 160–170.
   Google Scholar
• Atçalı, T., et al., 2022. Effects of favipiravir on hematologic parameters and bone marrow in the rats. Journal of Experimental and Clinical Medicine, 39 (1), 156–159.
   Google Scholar
• Chen, C., et al., 2020. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. Front Pharmacol.  12. doi:10.3389/fphar.2021.683296
   Web of Science ®Google Scholar
• Chen, Y.T., et al., 2011. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. Journal of Translational Medicine, 9 (1), 51.
   PubMed Web of Science ®Google Scholar
• Desco, M.C., et al., 2002. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes, 51 (4), 1118–1124.
   PubMed Web of Science ®Google Scholar
• Doi, Y., et al., 2020. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrobial Agents and Chemotherapy, 64 (12), e01897.
   PubMed Web of Science ®Google Scholar
• Driouich, J.S., et al., 2021. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nature Communications, 12 (1), 1735.
   PubMed Web of Science ®Google Scholar
• Du, Y.X., and Chen, X.P., 2020. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clinical Pharmacology & Therapeutics, 108 (2), 242–247.
   PubMed Web of Science ®Google Scholar
• Eşrefoğlu, M., et al., 2006. Antioxidative effect of melatonin, ascorbic acid and N-acetylcysteine on caerulein-induced pancreatitis and associated liver injury in rats. World Journal of Gastroenterology, 12 (2), 259–264.
   PubMed Web of Science ®Google Scholar
• Finberg, R.W., et al., 2021. US201 study: a phase 2, randomized proof-of-concept trial of favipiravir for the treatment of COVID-19. Open Forum Infectious Diseases, 8 (12), ofab563.
   PubMed Web of Science ®Google Scholar
• Furuta, Y., et al., 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research, 82 (3), 95–102.
   PubMed Web of Science ®Google Scholar
• Goldhill, D.H., et al., 2018. The mechanism of resistance to favipiravir in influenza. Proceedings of the National Academy of Sciences of the United States of America, 115 (45), 11613–11618.
   PubMed Web of Science ®Google Scholar
• Hanioka, N., et al., 2021. Favipiravir biotransformation in liver cytosol: species and sex differences in humans, monkeys, rats, and mice. Biopharmaceutics & Drug Disposition, 42 (5), 218–225.
   PubMed Web of Science ®Google Scholar
• Heunks, L.M., et al., 1999. Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease. The American Journal of Physiology, 277 (6), R1697–R1704.
   PubMedGoogle Scholar
• İzci-Çetinkaya, F., Karagöz, H., and Yıldız, O., 2020. COVID-19 Tedavisinde Favipiravir ve Hidroksiklorokinin Karaciğer Güvenliğinin Karşılaştırılması. Klimik Journal, 33 (3), 235–240.
   Google Scholar
• Karakuş, A., et al., 2021. In vitro cytotoxic effects of some Covid-19 drugs on lung cancer cells. Trakya University Journal of Natural Sciences, 22 (2), 173–177.
   Web of Science ®Google Scholar
• Kim, J.A., et al., 2018. Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models. Viruses, 10 (2), 72.
   PubMed Web of Science ®Google Scholar
• Kumar, P., et al., 2021. Favipiravir-induced liver injury in patients with coronavirus disease 2019. Journal of Clinical and Translational Hepatology, 9 (2), 276–278.
   PubMed Web of Science ®Google Scholar
• Lowry, O.H., et al., 1951. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193 (1), 265–275.,
   PubMed Web of Science ®Google Scholar
• Marra, F., et al., 2021. Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment. Drugs in R&D, 21 (1), 9–27.
   PubMed Web of Science ®Google Scholar
• Matkovics, B., 1988. Determination of enzyme activity in lipid peroxidation and glutathione pathways. Laboratoriumi Diagnosztika, 15, 248–250.
   Google Scholar
• Mendenhall, M., et al., 2011a. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Neglected Tropical Diseases, 5 (10), e1342.
   PubMed Web of Science ®Google Scholar
• Mendenhall, M., et al., 2011b. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrobial Agents and Chemotherapy, 55 (2), 782–787.
   PubMed Web of Science ®Google Scholar
• Mishima, E., et al., 2020. Uric acid elevation by favipiravir, an antiviral drug. The Tohoku Journal of Experimental Medicine, 251 (2), 87–90.
   PubMed Web of Science ®Google Scholar
• Musa, S., 2020. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? Arab Journal of Gastroenterology: The Official Publication of the Pan-Arab Association of Gastroenterology, 21 (1), 3–8.
   PubMed Web of Science ®Google Scholar
• Placer, Z.A., Cushman, L.L., and Johnson, B.C., 1966. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Analytical Biochemistry, 16 (2), 359–364.
   PubMed Web of Science ®Google Scholar
• Sedlak, J., and Lindsay, R.H., 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Analytical Biochemistry, 25, 192–205.
   PubMed Web of Science ®Google Scholar
• Sun, Y., Oberley, L.W., and Li, Y., 1988. A simple method for clinical assay of superoxide dismutase. Clinical Chemistry, 34 (3), 497–500.
   PubMed Web of Science ®Google Scholar
• Udwadia, Z.F., et al., 2021. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 103, 62–71.
   PubMed Web of Science ®Google Scholar
• Yamazaki, S., et al., 2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy, 27 (2), 390–392.
   PubMed Web of Science ®Google Scholar